SEC Form 4 · accession 0001966716-26-000010
Stoke Therapeutics, Inc. · STOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Allan
Officer — GENERAL COUNSEL & CORP SEC
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 4:18 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001623526
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 16, 2026 | S | 1,457 | $29.95 | D | 18,086 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.